- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Toshiba develops 3-D ultrasound probe
Add Toshiba to the list of companies developing 3-D ultrasoundtechnology. The company's Toshiba Medical Systems Europe subsidiaryin Zoetermeer, the Netherlands, has announced that it has developeda new transducer for 3-D imaging in obstetric
Add Toshiba to the list of companies developing 3-D ultrasoundtechnology. The company's Toshiba Medical Systems Europe subsidiaryin Zoetermeer, the Netherlands, has announced that it has developeda new transducer for 3-D imaging in obstetric applications.
Toshiba claims that the probe, called volume imaging transducer(VIT), is capable of real-time 3-D imaging, in which 3-D imagesare viewed during actual scanning. Most other 3-D ultrasound technologiesrequire a delay for image processing after cross-sectional slicesare acquired.
The VIT probe is a convex-array transducer that does not requireadditional devices or external computers. It can be connectedto a number of Toshiba scanners, including SSA-270A Super HG,SSH-140A Super HG, Eccocee CX, SSA-250A, and Tosbee.
In other Toshiba ultrasound news, the company's Toshiba AmericaMedical Systems subsidiary in Tustin, CA, said that it has setup a network of regional sales agents to sell its Capasee compactob/gyn scanner to private practice physicians. Toshiba believessuch a network is the most effective way to target office-basedphysicians, according to Dean Winter, director of ultrasound businessunit sales.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
